Six months of parathyroid hormone (1-84) administered concurrently versus sequentially with monthly ibandronate over two years: The PTH and ibandronate combination study (PICS) randomized trial

Journal of Clinical Endocrinology and Metabolism

Volumn 97, Issue 10, 2012, Pages 3522-3529

  Schafer, Anne L ^a,b   Sellmeyer, Deborah E ^a   Palermo, Lisa ^a   Hietpas, Jean ^a   Eastell, Richard ^d   Shoback, Dolores M ^c   Black, Dennis M ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXY TERMINAL TELOPEPTIDE; CITRATE CALCIUM; COLLAGEN; COLLAGEN TYPE 1 AMINOPROPEPTIDE; IBANDRONIC ACID; MULTIVITAMIN; PARATHYROID HORMONE; PLACEBO; UNCLASSIFIED DRUG; VITAMIN D;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE MASS; BONE TURNOVER; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONCURRENT DRUG ADMINISTRATION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HIP; HUMAN; HYPERCALCEMIA; HYPERCALCIURIA; INJECTION SITE CONTUSION; INJECTION SITE INFLAMMATION; MORNING DOSAGE; NAUSEA; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PILOT STUDY; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEQUENTIAL DRUG ADMINISTRATION; SPINE; TREATMENT DURATION;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; DRUG THERAPY, COMBINATION; FEMALE; FRACTURES, BONE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PARATHYROID HORMONE; PILOT PROJECTS; TREATMENT OUTCOME;

EID: 84867239128     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-1844     Document Type: Article

References (20)

1. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH 2001 Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434-1441 (Pubitemid 32402100)
2. Greenspan SL, Bone HG, Ettinger MP, Hanley DA, Lindsay R, Zanchetta JR, Blosch CM, Mathisen AL, Morris SA, Marriott TB 2007 Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann Intern Med 146:326-339 (Pubitemid 351650593)
3. Dempster DW, Cosman F, Kurland ES, Zhou H, Nieves J, Woelfert L, Shane E, Plavetiæ K, Müller R, Bilezikian J, Lindsay R 2001 Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res 16:1846-1853 (Pubitemid 32911491)
4. Hodsman AB, Bauer DC, Dempster DW, Dian L, Hanley DA, Harris ST, Kendler DL, McClung MR, Miller PD, Olszynski WP, Orwoll E, Yuen CK 2005 Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 26:688-703 (Pubitemid 41127277)
5. Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ 2003 The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349:1207-1215 (Pubitemid 37152030)
6. Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM 2003 The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 349:1216-1226 (Pubitemid 37152031)
7. Gasser JA, Ingold P, Venturiere-Rebmann A, Green JR, Chronic subcutaneous, but not single intravenous, dosing of rats with bisphosphonates results in reduced bone anabolic response to PTH. Program of the 28th Annual Meeting of the American Society for Bone and Mineral Research, Philadelphia, PA, 2006, poster FR386 (Abstract SA386)
8. Cosman F, Eriksen EF, Recknor C, Miller PD, Guañabens N, Kasperk C, Papanastasiou P, Readie A, Rao H, Gasser JA, Bucci- Rechtweg C, Boonen S 2011 Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis. J Bone Miner Res 26:503-511
9. Kurland ES, Cosman F, McMahon DJ, Rosen CJ, Lindsay R, Bilezikian JP 2000 Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J Clin Endocrinol Metab 85:3069-3076
10. Black DM, Bilezikian JP, Ensrud KE, Greenspan SL, Palermo L, Hue T, Lang TF, McGowan JA, Rosen CJ 2005 One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med 353:555-565 (Pubitemid 41138937)
11. Cosman F, Nieves J, Zion M, Woelfert L, Luckey M, Lindsay R 2005 Daily and cyclic parathyroid hormone in women receiving alendronate. N Engl J Med 353:566-575 (Pubitemid 41138938)
12. Lang TF, Li J, Harris ST, Genant HK 1999 Assessment of vertebral bone mineral density using volumetric quantitative CT. J Comput Assist Tomogr 23:130-137 (Pubitemid 29095483)
13. Khoo BC, Brown K, Cann C, Zhu K, Henzell S, Low V, Gustafsson S, Price RI, Prince RL 2009 Comparison of QCT-derived and DXA-derived areal bone mineral density and T scores. Osteoporos Int 20:1539-1545
14. Poole KE, Mayhew PM, Rose CM, Brown JK, Bearcroft PJ, Loveridge N, Reeve J 2010 Changing structure of the femoral neck across the adult female lifespan. J Bone Miner Res 25:482-491
15. Antoniucci DM, Sellmeyer DE, Bilezikian JP, Palermo L, Ensrud KE, Greenspan SL, Black DM 2007 Elevations in serum and urinary calcium with parathyroid hormone (1-84) with and without alendronate for osteoporosis. J Clin Endocrinol Metab 92:942-947 (Pubitemid 46465667)
16. Miller PD, Delmas PD, Lindsay R, Watts NB, Luckey M, Adachi J, Saag K, Greenspan SL, Seeman E, Boonen S, Meeves S, Lang TF, Bilezikian JP 2008 Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate. J Clin Endocrinol Metab 93:3785-3793
17. Boonen S, Marin F, Obermayer-Pietsch B, Simões ME, Barker C, Glass EV, Hadji P, Lyritis G, Oertel H, Nickelsen T, McCloskey EV 2008 Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 93:852-860
18. Ettinger B, San Martin J, Crans G, Pavo I 2004 Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 19:745-751 (Pubitemid 41094385)
19. Cosman F, Nieves JW, Zion M, Barbuto N, Lindsay R 2009 Retreatment with teriparatide one year after the first teriparatide course in patients on continued long-term alendronate. J Bone Miner Res 24:1110-1115
20. Glover SJ, Gall M, Schoenborn-Kellenberger O, Wagener M, Garnero P, Boonen S, Cauley JA, Black DM, Delmas PD, Eastell R 2009 Establishing a reference interval for bone turnover markers in 637 healthy, young, premenopausal women from the United Kingdom, France, Belgium, and the United States. J Bone Miner Res 24:389-397